Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961568 · ClinicalTrials.gov registry record · Phase 3
Cenobamate Open-Label Extension Study for YKP3089C025
A Phase 3 study, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT03961568: Completed Phase 3 study, sponsored by SK Life Science.
NCT03961568 is a Phase 3 study that has completed, run by SK Life Science. The registered enrollment target is 147 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03961568, a Phase 3 study, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)
Primary Outcome
Summary statistics for clinical laboratory test results and vital signs; and physical examination, neurologic examination and electrocardiogram (ECG) finding.
Interventions
- DRUG Cenobamate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2026-06-10 |
| Phase | Phase 3 |
What the finished NCT03961568 record still lists
NCT03961568 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Cenobamate is the first listed.
NCT03961568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03961568 about?
NCT03961568 is a clinical study titled "Cenobamate Open-Label Extension Study for YKP3089C025". 52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)
What is the current status of trial NCT03961568?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2019-08-13. Estimated completion is 2026-06-10.
What interventions are being tested in trial NCT03961568?
The interventions under investigation include: Cenobamate (DRUG).
Who is sponsoring clinical trial NCT03961568?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03961568's enrollment target sits among peer trials
147 1550th of 2000 higher than 450 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI